At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 59 enrolled
Drug / intervention
L-Carnitine +1 moredrug
Likely dose
L-Carnitine 2gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating L-Carnitine and Placebo for Multiple Sclerosis. Completed, enrolled 59 participants across 6 sites.
Detailed Summary
The objective of this study is to evaluate the efficacy of L-carnitine versus placebo in the treatment of fatigue in multiple sclerosis patients. This study will randomize 60 patients in a cross-over design. This study is sponsored by academic French health institutions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionMar 2013
Study CompletionJul 2013
TodayJul 2026
First PostedJun 23, 2010
Enrollment StartJun 1, 2010
Primary CompletionMar 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.0 years ago
Interventions
L-Carnitinedrug
2g oral solution , twice per day (morning/evening), during 3 months
Placebodrug
oral solution, twice per day (morning/evening), during 3 months